These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23635728)

  • 1. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial.
    Sørdal T; Inki P; Draeby J; O'Flynn M; Schmelter T
    Obstet Gynecol; 2013 May; 121(5):934-941. PubMed ID: 23635728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intrauterine device: a good thing revisited.
    Soper DE
    Obstet Gynecol; 2013 May; 121(5):919-920. PubMed ID: 23635725
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.
    Kaewrudee S; Taneepanichskul S; Jaisamraun U; Reinprayoon D
    Contraception; 1999 Jul; 60(1):25-30. PubMed ID: 10549449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a combined indomethacin and levonorgestrel-releasing intrauterine system on short-term postplacement bleeding profile: a randomized proof-of-concept trial.
    Fels LM; Costescu D; Vieira CS; Peipert JF; Lukkari-Lax E; Hofmann BM; Reinecke I; Klein S; Wiesinger K; Lindenthal B; Speer R
    Am J Obstet Gynecol; 2023 Mar; 228(3):322.e1-322.e15. PubMed ID: 36424684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.
    Christelle K; Norhayati MN; Jaafar SH
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD006034. PubMed ID: 36017945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
    Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
    Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial.
    Madden T; Proehl S; Allsworth JE; Secura GM; Peipert JF
    Am J Obstet Gynecol; 2012 Feb; 206(2):129.e1-8. PubMed ID: 22055339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use.
    Phupong V; Sophonsritsuk A; Taneepanichskul S
    Contraception; 2006 Mar; 73(3):253-6. PubMed ID: 16472565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.
    Cohen MA; Simmons KB; Edelman AB; Jensen JT
    Contraception; 2019 Nov; 100(5):391-396. PubMed ID: 31226322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levonorgestrel intrauterine system versus medical therapy for menorrhagia.
    Gupta J; Kai J; Middleton L; Pattison H; Gray R; Daniels J;
    N Engl J Med; 2013 Jan; 368(2):128-37. PubMed ID: 23301731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menstrual bleeding and spotting with the Levonorgestrel Intrauterine System (52 mg) during the first-year after insertion: a systematic review and meta-analysis.
    Maldonado LY; Sergison JE; Gao X; Hubacher D
    Am J Obstet Gynecol; 2020 May; 222(5):451-468.e9. PubMed ID: 31589865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial.
    Jensen JT; Lukkari-Lax E; Schulze A; Wahdan Y; Serrani M; Kroll R
    Am J Obstet Gynecol; 2022 Dec; 227(6):873.e1-873.e12. PubMed ID: 36096186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system.
    Lal S; Kriplani A; Kulshrestha V; Sharma M; Agarwal N
    Int J Gynaecol Obstet; 2010 May; 109(2):128-30. PubMed ID: 20223454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding and spotting with the levonorgestrel 13.5 mg intrauterine system: the impact of insertion timing.
    Shimoni N; Choudhury T; Goldman AR; Frondelli M; Chen PH
    Contraception; 2019 Jun; 99(6):340-344. PubMed ID: 30831104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding patterns with the 19.5 mg LNG-IUS, with special focus on the first year of use: implications for counselling.
    Beckert V; Ahlers C; Frenz AK; Gerlinger C; Bannemerschult R; Lukkari-Lax E
    Eur J Contracept Reprod Health Care; 2019 Aug; 24(4):251-259. PubMed ID: 31223042
    [No Abstract]   [Full Text] [Related]  

  • 17. Tranexamic acid: a review of its use in the management of menorrhagia.
    Wellington K; Wagstaff AJ
    Drugs; 2003; 63(13):1417-33. PubMed ID: 12825966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen.
    Weisberg E; Merki-Feld GS; McGeechan K; Fraser IS
    Contraception; 2015 Feb; 91(2):121-6. PubMed ID: 25459098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of irregular uterine bleeding and spotting associated with Norplant.
    Archer DF; Philput CA; Weber ME
    Hum Reprod; 1996 Oct; 11 Suppl 2():24-30. PubMed ID: 8982742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing levonorgestrel intrauterine system with hysteroscopic niche resection in women with postmenstrual spotting related to a niche in the uterine cesarean scar: a randomized, open-label, controlled trial.
    Zhang J; Zhu C; Yan L; Wang Y; Zhu Q; He C; He X; Ji S; Tian Y; Xie L; Liang Y; Xia W; Mol BW; Huirne JAF
    Am J Obstet Gynecol; 2023 Jun; 228(6):712.e1-712.e16. PubMed ID: 36935068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.